共查询到20条相似文献,搜索用时 93 毫秒
1.
中草药提取物复配化妆品乳液延缓皮肤衰老实验研究 总被引:3,自引:0,他引:3
目的 研究当归等5味中草药提取物复配护肤品乳液的抗皮肤衰老作用. 方法 将60只12个月龄雌性昆明种小鼠随机分成3组(n=20), 自然衰老正常对照组(N组)、低剂量中草药提取物组(L组)、高剂量中草药提取物组(H组); 另将20只3个月龄小鼠组成年青对照组(Y组).L组用4%中草药提取物复配的化妆品乳液外涂, H组用16%中草药提取物复配的化妆品乳液外涂, N组和Y组用不含中草药提取物成分的化妆品基质乳液外涂.连续涂抹60 d, 取小鼠背部涂抹部位皮肤, 测定皮肤组织匀浆中的羟脯氨酸(HYP)、超氧化物歧化酶(SOD)及过氧化脂质(LPO)代谢产物丙二醛(MDA)、脂褐质(LF)的含量. 结果 L组SOD活力较Y组明显下降, 而MDA、LF的含量明显增加.L组及H组小鼠皮肤匀浆中的HYP含量分别达到(30.85±3.71)和(35.46±3.54) mg8226;g-1, SOD含量分别达到(17.92±0.58)和(20.38±0.71) U8226;mL-1, MDA含量达到为(6.92±1.38)和(5.96±1.25)mmol8226;g-1, LF含量达到(6.13±1.73)和(4.89±1.15) μg8226;g-1; 与对照组比较, 均差异有显著性(P< 0.05).结论 当归等5味中药提取物复配护肤品乳液具有较显著的抗皮肤衰老作用. 相似文献
2.
目的 建立液相色谱-串联质谱(LC-MS/MS)法评价免疫抑制剂麦考酚酸酯(MMF)在术后2~3周肾移植患者中连续口服的药动学特点. 方法 受试者口服MMF(0.75 g,bid),2~3周后用LC-MS/MS法测定血浆中活性代谢物麦考酚酸(MPA)的浓度,并用非房室模型计算药动学参数. 结果 MPA在0.1~51.2 μg8226;mL-1 范围内线性关系良好,批内、批间RSD<10%,准确度在90%~110%,方法学验证符合生物样品分析方法的要求. MMF的体内代谢呈明显的个体差异,药动学参数:AUC0 t为(36.65±11.42) mg8226;h8226;L-1; AUC0 ∞为(43.34±18.02) mg8226;h8226;L-1; Cmax为(15.89±5.77) mg8226;L-1; t max为(1.08±0.47) h; t1/2为(3.34±1.63) h; MRT0 t为(3.42±1.12) h; Vd为(194.88±156.45) L; CL为(41.02±18.19) L8226; h-1. 结论 LC MS/MS法用于MPA血浆浓度测定,操作简便,结果灵敏、特异性好. 相似文献
3.
美西律致超敏反应综合征1例 总被引:2,自引:0,他引:2
患者, 女, 47岁. 因全身红斑丘疹、微痒1周入院. 患者1周前无明显诱因颜面、前臂出现米粒大红斑丘疹, 微痒, 渐增多, 波及躯干下肢, 当地以“病毒疹”给予氯雷他定、维生素C、利巴韦林、复方甘草酸苷及中药等治疗, 红斑丘疹增多, 泛发全身, 融合成片, 躯干为重, 颜面出现红肿, 伴发热畏寒, 体温37.7~38.0 ℃, 病情进行性加重. 患者1个月前因心慌于外院做动态心电图, 诊断为室性期前收缩, 予美西律片,, 每次100 mg, tid, 服用1个月后出现皮疹. 否认药物、食物致变态反应史. 体检:体温38.2 ℃, 脉搏90次8226;min-1, 呼吸20次8226;min-1, 血压90/68 mmHg(1 mmHg=0.133 kPa), 精神差, 耳后、颈侧可触及数个绿豆大淋巴结, 无压痛, 咽充血, 心、肺、腹无异常. 皮肤科检查:全身皮肤泛发米粒大红斑丘疹, 融合成片, 压之退色, 躯干为重, 颜面红肿. 实验室检查:血常规示白细胞20.9×1098226;L -1, 血小板357×1098226;L -1, 中性粒细胞绝对值12.8×1098226;L-1, N 0.609, 淋巴细胞绝对值3.7×1098226;L -1, L 0.176, 单核细胞绝对值1.58×1098226;L -1, 分类7.56%, 嗜酸性粒细胞绝对值2.52×1098226;L -1, 分类12%; C 反应蛋白(CRP)19 mg8226;L -1; 肝功能示丙氨酸氨基转移酶126 U8226;L-1, 天冬氨酸氨基转移酶135 U8226;L -1, 谷氨酰转肽酶82 U8226;L-1, 碱性磷酸酶306 U8226;L-1, 乳酸脱氢酶404 U8226;L -1, 腺苷脱氨酶29 U8226;L -1, α-羟丁酸脱氢酶271 U8226;L -1; 肾功能、电解质、血糖、免疫球蛋白、补体、AS0、RF、ANA、肝炎免疫、病毒检测(包括麻疹病毒、风疹病毒、EB病毒及巨细胞病毒), 尿、大便常规均无异常. 心电图示窦性心律, T波改变. 胸部X线片示两肺纹理增多增粗. B超无异常. 诊断为药物超敏反应综合征. 停用美西律, 予甲泼尼龙 80 mg8226;d -1、复方甘草酸苷及氯雷他定等治疗, 红斑丘疹有所消退, 肝酶较前恢复, 病情好转. 相似文献
4.
患者,女,30岁.因心悸,怕热多汗,消瘦2个月,于2010年9月3日来我院就诊.入院体检:体温37.2 ℃,心率93次8226;min-1,呼吸20次8226;min-1,血压110/70 mmHg(1 mmHg=0.133 kPa),实验室检查血白细胞 5.9×1098226;L-1,中性粒细胞计数3.4×1098226;L-1;血生化丙氨酸氨基转移酶(alanine aminotransferase,ALT)22 U8226;L-1、天冬氨酸氨基转移酶(aspartate aminotransferase,AST) 28 U8226;L-1等均正常;尿常规正常.甲状腺功能检测:总三碘甲状腺原氨酸3.19 nmol8226;L-1,甲状腺素总量16.81 nmol8226;L-1,促甲状腺激素0.01 U8226;L-1,游离三碘甲状腺原氨酸11.24 pmol8226;L-1,游离甲状腺素2.49 pmol8226;L-1.甲状腺超声显示:甲状腺回声不均并血流丰富改变.诊断:甲状腺机能亢进(甲亢).给予甲巯咪唑片10 mg,bid,普萘洛尔片10 mg,tid,po.用药15 d后患者躯干、四肢及面部出现红色皮疹,高出皮面,伴有刺痒,以双髋部及膝盖等处为著,并有食欲下降、恶心等症状.体检:体温37.1 ℃,心率95次8226;min-1.复查血常规及生化:白细胞3.2×1098226;L-1,中性粒细胞1.8×1098226;L-1,ALT 175 U8226;L-1,AST 67 U8226;L-1.考虑为甲巯咪唑引起的白细胞减少、肝功能异常及皮疹,遂停用甲巯咪唑,其他治疗不变,并给予还原型谷胱甘肽1.2 g + 0.9%氯化钠注射液250 mL,qd,静脉滴注;氯雷他定10 mg,qd,po;利可君40 mg,tid,po,盐酸小檗胺4片,tid,po.6 d后复查血白细胞 4.37×1098226;L-1,中性粒细胞3.0×1098226;L-1,皮疹逐渐消失.继续给予保肝治疗,1周后复查肝功能:ALT 24 U8226;L-1,AST 18 U8226;L-1.逐步恢复至正常值 相似文献
5.
艾司西酞普兰与文拉法辛治疗难治性抑郁症的对照研究 总被引:1,自引:0,他引:1
目的 探讨艾司西酞普兰对难治性抑郁症患者的疗效和安全性. 方法 68例难治性抑郁症的住院患者随机分为治疗组和对照组各34例, 治疗组给予艾司西酞普兰,起始剂量10 mg8226;d-1,早餐后服,根据病情调整10~20 mg8226;d-1,平均剂量(16.62±3.65) mg8226;d-1. 对照组给予文拉法辛缓释剂,起始剂量75 mg8226;d-1,早餐后服用,7~10 d加至治疗量150~225 mg8226;d-1,平均剂量(175.54±20.50) mg8226;d-1. 两组疗程均6周. 采用汉密尔顿抑郁量表(HAMD)评定疗效,不良反应和安全性采用不良反应量表(TESS)及实验室检查评定. 结果 有效率和痊愈率治疗组分别为58.8%,20.6%;对照组分别为61.8%,23.5%;两组比较差异无显著性(P>0.05). TESS评定显示,两组不良反应发生率差异无显著性(P>0.05). 结论 艾司西酞普兰治疗难治性抑郁症的疗效与文拉法辛相似,起效快,不良反应较轻. 相似文献
6.
目的 建立高效液相色谱法测定血清和组织烯丙基半胱氨酸(SAC)浓度的 方法 , 并进行组织分布研究. 方法 采用Hypersil ODS2 色谱柱, 以50 mmol8226;L-1 醋酸盐缓冲液 (pH 5.8 ):甲醇:乙腈(50:22:28)为流动相; 柱温为35 ℃ , 荧光检测激发波长为350 nm , 发射波长为455 nm.样品的预处理后邻苯二甲醛(OPA)-2-巯基乙醇柱前衍生; 进样10 μL. 结果 血清样品在2~120 mg8226;L-1浓度范围内, 线性关系良好; 组织样品在2~120 mg8226;g-1浓度范围内, 线性关系良好.低、中、高3种浓度的萃取回收率为70.9%~83.5%; 相对回收率为90.2%~110.0%; 日内、日间RSD为4.1%~7.7%.肾脏达峰浓度Cmax为65.7 mg8226;kg-1, 肝脏为58.1 mg8226;kg-1, 脾脏为51.3 mg8226;kg-1, 心脏为43.3 mg8226;kg-1, 肺为35.1 mg8226;kg-1, 脑组织为26.7 mg8226;kg-1 ; 各组织AUC 0~8肾脏为171.9 mg8226;h8226;kg-1, 心脏为113.9 mg8226;h8226;kg-1, 肝脏为107.2 mg8226;h8226;kg-1, 脾脏为90.4 mg8226;h8226;kg-1, 肺为93.6 mg8226;h8226;kg-1,脑组织为79.8 mg8226;h8226;kg-1. 结论 该法简便、快速、准确、灵敏、选择性强, SAC在大鼠体内分布广泛, 其中肾脏分布较多, 而在脑组织中分布较少. 相似文献
7.
喹硫平治疗精神分裂症30例 总被引:2,自引:2,他引:0
目的 考察喹硫平治疗精神分裂症的有效性及安全性. 方法 将60例精神分裂症患者分为治疗组和对照组, 每组30例.治疗组给予喹硫平, 初始剂量100 mg8226;d-1, 2周内加至400~800 mg8226;d-1, 以后3周内视病情及不良反应调整剂量, 最大剂量1 200 mg8226;d-1, 平均(728.3±199.9) mg8226;d-1.对照组给予利培酮, 起始剂量1 mg8226;d-1, 2周后加至治疗量3~6 mg8226;d-1, 平均(4.9±0.9) mg8226;d-1.疗程均为8周.两组根据情况给予苯海索、氮类药或普萘洛尔等对症处理, 以阴性和阳性症状量表(PANSS)、不良反应量表(TESS)分别评定疗效、病情严重程度和不良反应. 结果 治疗组与对照组的显效率均为70.0%, 有效率分别为90.0%和86.7%.两组在治疗前PANSS评分差异无显著性, 在治疗8周末, 两组PANSS评分较治疗前显著下降, 均差异有极显著性(均P< 0.01).两组比较差异无显著性(P>0.05).治疗组的不良反应较对照组少而轻.结论 喹硫平可显著改善精神分裂症症状, 且不良反应发生率低, 是一种安全有效的抗精神病药物. 相似文献
8.
目的 考察头孢他啶对奈替米星在受试者体内药动学的影响,为临床合理用药提供依据. 方法 12例受试者在单剂量静脉滴注奈替米星(单用组)或奈替米星加头孢他啶(联用组)后,采用高效液相色谱 间接光度法测定不同时间点血清及尿液中奈替米星浓度,计算其药动学参数及尿药回收率. 结果 单用、合用头孢他啶后奈替米星的体内过程均符合二房室开放模型,其药动学参数单用组AUC0-t,t1/2β,CL与0~24 h尿药回收率分别为(52.93±5.58) mg8226;L-18226;h、(3.68±0.33) h、(4.49±0.53) L8226;h-1与72.22%,联用组分别为(71.81±8.03 )mg8226;L-18226;h、(5.06±0.57) h、(2.95±0.37) L8226;h-1与59.20%. 两组比较差异有显著性. 结论 奈替米星与头孢他啶联用后,其消除过程减慢,连续应用可能导致药物体内蓄积,二者合用时应适当减少奈替米星的剂量. 相似文献
9.
连芪消渴胶囊对糖尿病肾病模型大鼠晚期糖基化终末产物与氧化应激损伤的影响 总被引:1,自引:1,他引:0
[摘要]目的通过观察连芪消渴胶囊对糖尿病肾损害大鼠晚期糖基化终末产物(AGEs)及氧化应激反应的影响,探讨该药对糖尿病大鼠肾损害的干预作用和初步机制。方法大鼠高糖高脂饲料喂养4周并腹腔注射低剂量(30 mg8226;kg 1)链脲佐菌素(STZ),诱发糖尿病大鼠肾损伤模型,分为正常对照组,模型组,连芪消渴胶囊低、中、高剂量(2, 4, 8 g8226;kg 18226;d 1)组,二甲双胍组(0.2 g8226;kg 18226;d 1),治疗8周取血、留尿、取肾组织,检测大鼠血糖、尿微量清蛋白(U mALB)、肾组织超氧化物歧化酶(SOD)、丙二醛(MDA)、血AGEs、生长转化因子(TGF β1)、肿瘤坏死因子(TNF α)等,肾组织苏木精 伊红(HE)染色的病理变化。结果连芪消渴胶囊组血糖(18.67±2.52) mmol8226;L 1,MDA(1.78±0.39) nmol8226;g 1,U mALB(41.84±8.23) μg8226;L 1,血AGEs(116.91±19.96) ng8226;mL 1,TGF β1(33.22±9.94) ng8226;mL 1,TNF α(54.01±17.55) pg8226;mL 1,均较模型组下降(P<0.05);SOD(190.11±15.88) U8226;mg 1,比模型组升高(P<0.05);肾功能和肾组织病理得到改善,其中连芪消渴胶囊大剂量组治疗效果显著。结论高糖高脂饲料联合低剂量STZ成功制备大鼠糖尿病肾病模型;连芪消渴胶囊能明显降低AGEs水平,减轻糖尿病肾损害,其机制可能与抑制AGEs的产生、降低氧化应激反应、抑制炎症因子等作用有关。 相似文献
10.
目的 探讨齐拉西酮治疗首发精神分裂症的有效性与安全性. 方法 将76例未服药的首发精神分裂症患者随机分为治疗组37例, 对照组39例. 治疗组给予齐拉西酮, 初始剂量为20~40 mg8226;d-1 , bid, 餐时口服, 15 d内可视病情调整至最大剂量80~160 mg8226;d-1 , 平均终末治疗剂量(90.1±10.2) mg8226;d-1. 对照组给予利培酮, 初始剂量为0.5~1.0 mg8226;d-1 , 15 d内可视病情调整至2~6 mg8226;d-1 , 平均治疗剂量(3.5 ±0.6) mg8226;d-1. 疗程8周. 于治疗前和治疗第2, 4, 6, 8周末采用阳性症状与阴性症状量表(PANSS)评定临床疗效, 不良反应症状量表(TESS)评定不良反应. 结果 治疗第8周末治疗组和对照组PANSS评分均非常显著低于治疗前(P<0.01), 但组间差异均无显著性(P>0.05), 两组有效率分别为91.9%和89.8%, 差异无显著性(P>0.05). 治疗组的不良反应较少, 两组差异无显著性(P>0.05). 结论 齐拉西酮治疗首发精神分裂症的疗效与利培酮相当, 是安全、有效的新型抗精神病药物. 相似文献
12.
Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.
Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.相似文献
13.
15.
《Critical reviews in toxicology》2013,43(5-6):327-369
AbstractThe uptake of metals from food and water sources by insects is thought to be additive. For a given metal, the proportions taken up from water and food will depend both on the bioavailable concentration of the metal associated with each source and the mechanism and rate by which the metal enters the insect. Attempts to correlate insect trace metal concentrations with the trophic level of insects should be made with a knowledge of the feeding relationships of the individual taxa concerned. Pathways for the uptake of essential metals, such as copper and zinc, exist at the cellular level, and other nonessential metals, such as cadmium, also appear to enter via these routes. Within cells, trace metals can be bound to proteins or stored in granules. The internal distribution of metals among body tissues is very heterogeneous, and distribution patterns tend to be both metal and taxon specific. Trace metals associated with insects can be both bound on the surface of their chitinous exoskeleton and incorporated into body tissues. The quantities of trace meals accumulated by an individual reflect the net balance between the rate of metal influx from both dissolved and particulate sources and the rate of metal efflux from the organism. The toxicity of metals has been demonstrated at all levels of biological organization: cell, tissue, individual, population, and community. Much of the literature pertaining to the toxic effects of metals on aquatic insects is based on laboratory observations and, as such, it is difficult to extrapolate the data to insects in nature. The few experimental studies in nature suggest that trace metal contaminants can affect both the distribution and the abundance of aquatic insects. Insects have a largely unexploited potential as biomonitors of metal contamination in nature. A better understanding of the physico-chemical and biological mechanisms mediating trace metal bioavailability and exchange will facilitate the development of general predictive models relating trace metal concentrations in insects to those in their environment. Such models will facilitate the use of insects as contaminant biomonitors. 相似文献
16.
Petrikovics I McGuinn WD Sylvester D Yuzapavik P Jiang J Way JL Papahadjopoulos D Hong K Yin R Cheng TC DeFrank JJ 《Drug delivery》2000,7(2):83-89
This study describes a new approach for organophosphorous (OP) antidotal treatment by encapsulating an OP hydrolyzing enzyme, OPA anhydrolase (OPAA), within sterically stabilized liposomes. The recombinant OPAA enzyme was derived from Alteromonas strain JD6. It has broad substrate specificity to a wide range of OP compounds: DFP and the nerve agents, soman and sarin. Liposomes encapsulating OPAA (SL)* were made by mechanical dispersion method. Hydrolysis of DFP by (SL)* was measured by following an increase of fluoride ion concentration using a fluoride ion selective electrode. OPAA entrapped in the carrier liposomes rapidly hydrolyze DFP, with the rate of DFP hydrolysis directly proportional to the amount of (SL)* added to the solution. Liposomal carriers containing no enzyme did not hydrolyze DFP. The reaction was linear and the rate of hydrolysis was first order in the substrate. This enzyme carrier system serves as a biodegradable protective environment for the recombinant OP-metabolizing enzyme, OPAA, resulting in prolongation of enzymatic concentration in the body. These studies suggest that the protection of OP intoxication can be strikingly enhanced by adding OPAA encapsulated within (SL)* to pralidoxime and atropine. 相似文献
17.
《Expert opinion on investigational drugs》2013,22(1):79-86
Advances in the molecular biological knowledge of neuronal nicotinic acetylcholine receptors (nAChRs) have led to a growing interest by the pharmaceutical industry in the development of novel compounds that selectively modulate nAChR function. The ability of (-)-nicotine, an activator of nAChRs, to enhance attentional aspects of cognition in animals and humans, to exert neuroprotective and anxiolytic-like effects, and presumably to mediate the negative correlation between smoking and Alzheimer's (and Parkinson's) Disease, has focused interest on the potential therapeutic utility of modulators of nAChR function for treatment of some of the deficits associated with these progressive, neurodegenerative conditions. Numerous compounds are known which activate nAChRs and which might serve as lead compounds toward the development of such agents. The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favourable side-effect profiles than existing agents. This broader class of agents, collectively called cholinergic channel modulators (ChCMs), is anticipated to encompass compounds which would have more favourable side-effect profiles than existing agents, which generally exhibit low selectivity. This selectivity may be achieved by preferentially activating some subtypes of nAChRs (i.e., Cholinergic Channel Activators, ChCAs) or inhibiting the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs). An overview of the biology of nAChRs and the rationale for the use of ChCMs for the treatment of dementia related to neurodegenerative diseases are presented, followed by a discussion of lead compounds and compounds under consideration for clinical evaluation. 相似文献
18.
Alberto García-Lled Javier Gmez-Pavn Juan Gonzlez del Castillo Teresa Hernndez-Sampelayo Mari Cruz Martín-Delgado Francisco Javier Martín Snchez Manuel Martínez-Sells Jos María Molero García Santiago Moreno Guilln Fernando Rodríguez-Artalejo Julin Ruiz-Galiana Rafael Cantn Pilar De Lucas Ramos Alejandra García-Botella Emilio Bouza 《Rev Esp Quimioter》2022,35(2):115
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation. 相似文献
19.
Chang Min Kim Kun Ho Son Sung Hwan Kim Hyun Pyo Kim 《Archives of pharmacal research》1991,14(4):305-310
In order to find out the values of the steroid resources for the future use. the compositions and contents of steroidal sapogenins
from 13 domestic plants have been investigated. As a result,Dioscorea nipponica, D. quinqueloba andSmilax china were found to have large amount of diosgenin. And pennogenin inTrillium kamtschaticum andParis verticillata, yuccagenin inAllium fistulosum, hecogenin inAgave americana and neochlorogenin inSolanum nigum were appeared to be major steroidal sapogenins. 相似文献